Free Trial

Stratos Wealth Partners LTD. Has $324,000 Position in Solventum Corporation (NYSE:SOLV)

Solventum logo with Medical background

Stratos Wealth Partners LTD. trimmed its stake in Solventum Corporation (NYSE:SOLV - Free Report) by 50.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,256 shares of the company's stock after selling 4,355 shares during the period. Stratos Wealth Partners LTD.'s holdings in Solventum were worth $324,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SOLV. Proficio Capital Partners LLC purchased a new position in shares of Solventum in the fourth quarter valued at $1,545,000. Raymond James Financial Inc. bought a new stake in shares of Solventum during the 4th quarter valued at $18,583,000. Sequoia Financial Advisors LLC raised its stake in shares of Solventum by 27.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 7,317 shares of the company's stock valued at $483,000 after purchasing an additional 1,580 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Solventum by 48.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company's stock valued at $45,000 after purchasing an additional 223 shares during the period. Finally, Avantax Advisory Services Inc. raised its stake in shares of Solventum by 2.2% during the 4th quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company's stock valued at $584,000 after purchasing an additional 192 shares during the period.

Analysts Set New Price Targets

SOLV has been the subject of a number of recent research reports. Morgan Stanley raised Solventum from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $80.00 to $103.00 in a research note on Tuesday. Argus raised Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target for the company in a research report on Tuesday, July 1st. Piper Sandler raised Solventum from a "neutral" rating to an "overweight" rating and upped their price target for the company from $78.00 to $87.00 in a research report on Monday, May 19th. Finally, KeyCorp began coverage on Solventum in a research report on Friday, June 6th. They set a "sector weight" rating for the company. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $84.38.

View Our Latest Stock Report on Solventum

Solventum Trading Down 0.5%

Shares of SOLV stock opened at $73.69 on Wednesday. The firm has a market capitalization of $12.75 billion, a PE ratio of 34.11, a PEG ratio of 1.90 and a beta of 0.55. The stock has a fifty day simple moving average of $73.84 and a two-hundred day simple moving average of $72.56. The company has a debt-to-equity ratio of 2.40, a quick ratio of 0.85 and a current ratio of 1.19. Solventum Corporation has a 52-week low of $47.16 and a 52-week high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.15. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.02 billion. Solventum had a net margin of 4.55% and a return on equity of 31.01%. The firm's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.08 earnings per share. On average, analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

About Solventum

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Read More

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Solventum Right Now?

Before you consider Solventum, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.

While Solventum currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Time to Cash Out? 5 Stocks to Drop Before Earnings
Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines